Supported by the National Eye Institute of the National Institutes of Health under Award Numbers 1R01EY029595.
Disclosure: M. Emamverdi, None; C. Vatanatham, None; S. Fasih-Ahmad, None; Z. Wang, None; Z. Mishra, None; A. Jain, None; A. Ganegoda, None; M.E. Clark, None; A. Habibi, None; M. Ashrafkhorasani, None; C. Owsley, Johnson & Johnson Vision (F); C.A. Curcio, Genentech/Hoffman LaRoche (F), Regeneron (F), Heidelberg Engineering (C, F, R); Apellis (C), Astellas (C), Boehringer Ingelheim (C), Character Biosciences (C), Osanni (C), and Annexon (outside this project); Z.J. Hu, Heidelberg Engineering (C, F, R); S.R. Sadda, 4DMT (C), AbbVie (C), Alexion (C), Allergan Inc. (C), Alnylam Pharmaceuticals (C), Amgen Inc. (C), Apellis Pharmaceuticals Inc. (C), Astellas (C), Bayer Healthcare Pharmaceuticals (C), Biogen MA Inc. (C), Boehringer Ingelheim (C), Catalyst Pharmaceuticals Inc. (C), Centervue Inc. (C, F), GENENTECH (C), Gyroscope Therapeutics (C), Hoffman La Roche Ltd. (C), Iveric Bio (C), Janssen Pharmaceuticals Inc. (C), Merck & Co. Inc. (C), Nanoscope (C), Notal Vision Inc. (C), Optos Inc. (C, F), Oxurion/Thrombogenics (C), Oyster Point Pharma (C), Pfizer Inc. (C), Regeneron Pharmaceuticals Inc. (C), Samsung Bioepis (C), Vertex Pharmaceuticals Incorporated (C), Carl Zeiss Meditec (C, F, R), Heidelberg Engineering (C, F, R), Novartis Pharma AG (C, R), Nidek Incorporated (F, R); Topcon Medical Systems Inc. (C, F, R)